Cargando…

Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report

BACKGROUND: Pulmonary carcinosarcoma (PCS) is a rare primary lung malignancy and has a poor prognosis among lung tumor histological subtypes. However, an appropriate treatment strategy has not been developed for unresectable PCS. CASE PRESENTATION: A 65-year-old man who was diagnosed with PCS was tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanimoto, Azusa, Takeuchi, Shinji, Kotani, Hiroshi, Yamashita, Kaname, Yamada, Tadaaki, Ohtsubo, Koushiro, Ebi, Hiromichi, Ikeda, Hiroko, Yano, Seiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291996/ https://www.ncbi.nlm.nih.gov/pubmed/30541518 http://dx.doi.org/10.1186/s12890-018-0757-7

Ejemplares similares

Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
por: Adachi, Yuta, et al.
Publicado: (2020)

Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
por: Tanimoto, Azusa, et al.
Publicado: (2014)

Multiple Malignant Lymphomas of the Bile Duct Developing after Spontaneous Regression of an Autoimmune Pancreatitis-like Mass
por: Ohtsubo, Koushiro, et al.
Publicado: (2020)

Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
por: Sakaguchi, Hiroyuki, et al.
Publicado: (2021)

Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1‐rearranged tumor cells
por: Suzuki, Chiaki, et al.
Publicado: (2022)

Patient‐derived xenograft models of non‐small cell lung cancer for evaluating targeted drug sensitivity and resistance
por: Kita, Kenji, et al.
Publicado: (2019)

Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
por: Nishikawa, Tadaaki, et al.
Publicado: (2017)

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
por: Nanjo, Shigeki, et al.
Publicado: (2015)

Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report
por: Sawayama, Saki, et al.
Publicado: (2022)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
por: Nakade, Junya, et al.
Publicado: (2014)

Gastric carcinosarcoma with FGFR2 amplification under long-term control with pazopanib: a case report and literature review
por: Hayashi, Hirokatsu, et al.
Publicado: (2022)

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
por: Wang, Rong, et al.
Publicado: (2020)

Impact of MET inhibition on small‐cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway
por: Taniguchi, Hirokazu, et al.
Publicado: (2017)

In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET
por: Arai, Sachiko, et al.
Publicado: (2017)

Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2020)

Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review
por: Nishiyama, Akihiro, et al.
Publicado: (2021)

mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF
por: Ishikawa, Daisuke, et al.
Publicado: (2013)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Trametinib overcomes KRAS‐G12V–induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2021)

Severe heparin-induced thrombocytopenia: when the obvious is not obvious, a case report
por: Cormack, Graham M, et al.
Publicado: (2007)

Straight roads into nowhere – obvious and not-so-obvious biological models for ferrophobic surfaces
por: Konrad, Wilfried, et al.
Publicado: (2022)

The SMYD family proteins in immunology: An update of their obvious and non-obvious relations with the immune system
por: Rubio-Tomás, Teresa
Publicado: (2021)

Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers
por: Ebi, Hiromichi, et al.
Publicado: (2014)

Bilateral Integrative Medicine, Obviously
por: Stumpf, Steven H., et al.
Publicado: (2006)

The Surprising Value of Obvious Insights
por: Grant, Adam
Publicado: (2019)

Formulation Patents and Dermatology and Obviousness
por: Mei, Dan-Feng, et al.
Publicado: (2011)

Trends of uterine carcinosarcoma in the United States
por: Matsuo, Koji, et al.
Publicado: (2018)

Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors
por: Taniguchi, Hirokazu, et al.
Publicado: (2016)

True Carcinosarcoma of the Esophagus: Report of a Case
por: Yamamoto, Yuji, et al.
Publicado: (2008)

What's inside the proton: the invisibly obvious
por: Comay, Ofer
Publicado: (2011)

Anal Pain and Constipation – Beyond the Obvious
por: Barbeiro, Sandra, et al.
Publicado: (2015)

STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis
por: Yanagimura, Naohiro, et al.
Publicado: (2022)

Clinical utility of CA-125 in the management of uterine carcinosarcoma
por: Matsuo, Koji, et al.
Publicado: (2018)

Saul-Wilson Syndrome Missense Allele Does Not Show Obvious Golgi Defects in a C. elegans Model
por: Zafra, Isabella, et al.
Publicado: (2021)

Carcinosarcoma of the ovary
por: Harris, M A, et al.
Publicado: (2003)

Carcinosarcoma in the Cecum
por: Ryu, Youngjoon, et al.
Publicado: (2012)

Carcinosarcoma of uterus
por: Tuan, Ho Xuan, et al.
Publicado: (2023)

Androgen replacement therapy for cancer‐related symptoms in male: result of prospective randomized trial (ARTFORM study)
por: Izumi, Kouji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fn0c4snsq0o76drfg16r30n6ls